Top

Published in:

27-12-2023 | Dimethyl Fumarate | Original Article

Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis

Authors: Valentina Andreozzi, Rocco Capuano, Sara Scannapieco, Francesca Barra, Beatrice d’Arco, Caterina Giordano, Miriam Caterino, Umberto De Marca, Federico Di Filippo, Maria Di Gregorio, Paolo Barone

Published in: Neurological Sciences | Issue 6/2024

Abstract

Introduction

Lymphopenia is a known side effect of dimethyl fumarate (DMF), a disease-modifying therapy (DMT) for patients with multiple sclerosis (pwMS). A body mass index ≥ 30 kg/m² has been identified as a protective factor; however, no data are available on lymphopenia in pwMS undergoing to weight loss due to bariatric surgery.

Methods

We described two pwMS with history of bariatric surgery who started DMF as DMT.

Results

The two pwMS experienced persistent lymphopenia during DMF-treatment, which was resolved after its discontinuation.

Conclusions

Several mechanisms might modify DMF pharmacokinetic profiles after bariatric surgery and its bioavailability. Absolute lymphocyte count should be monitored in pwMS treated with DMF and history of bariatric surgery and weight loss.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107. https://doi.org/10.1056/NEJMoa1114287CrossRefPubMed

Fox EJ, Buckle GJ, Singer B, Singh V, Boster A (2019) Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist. NeurolClinPract 9(1):53–63. https://doi.org/10.1212/cpj.0000000000000567CrossRef

Dello Russo C, Scott KA, Pirmohamed M (2021) Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. PharmacolTher 219:107710. https://doi.org/10.1016/j.pharmthera.2020.107710CrossRef

Lucchini M, Prosperini L, Buscarinu MC et al (2021) Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. J Neurol 268:2238–2245. https://doi.org/10.1007/s00415-021-10412-0CrossRefPubMedPubMedCentral

Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L (2016) Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. MultScler 22(8):1061–1070. https://doi.org/10.1177/1352458515608961CrossRef

Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y (2018) Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol 9:5. https://doi.org/10.3389/fneur.2018.00005CrossRefPubMedPubMedCentral

Dinoto A, Sartori A, Cheli M, Pasquin F, Baldini S, Bratina A, Bosco A, Manganotti P (2022) Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: prevalence, predicting factors and clinical outcomes. MultSclerRelatDisord 57:103357. https://doi.org/10.1016/j.msard.2021.103357CrossRef

Sainz de la Maza S, Sabin Muñoz J, Pilo de la Fuente B, Thuissard I, Andreu-Vázquez C, Galán Sánchez-Seco V, Salgado-Cámara P, Costa-Frossard L, Monreal E, Ayuso-Peralta L, García-Vasco L, García-Domínguez JM, Martínez-Ginés ML, Muñoz Fernández C, Díaz-Díaz J, Oreja-Guevara C, Gómez-Moreno M, Martín H, Rubio-Flores L, Blasco MR, Villar-Guimerans LM, Aladro Y; Dimethyl Fumarate Study Group (2022) Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. Mult Scler Relat Disord 59:103669. https://doi.org/10.1016/j.msard.2022.103669

Ravn J, Jensen HB, Kant M, Andersen PB, Góra MK, Sejbaek T (2022) Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. MultSclerRelatDisord 67:104081. https://doi.org/10.1016/j.msard.2022.104081CrossRef

10.

Sainz de la Maza S, Medina S, Villarrubia N, Costa-Frossard L, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, Álvarez-Cermeño JC, Villar LM (2019) Factors associated with dimethyl fumarate-induced lymphopenia. J Neurol Sci 398:4–8. https://doi.org/10.1016/j.jns.2019.01.007.

11.

Angeles PC, Robertsen I, Seeberg LT, Krogstad V, Skattebu J, Sandbu R, Åsberg A, Hjelmesaeth J (2019) The influence of bariatric surgery on oral drug bioavailability in patients with obesity: a systematic review. Obes Rev 20(9):1299–1311. https://doi.org/10.1111/obr.12869CrossRefPubMedPubMedCentral

12.

Edwards A, Ensom MH (2012) Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 46(1):130–136. https://doi.org/10.1345/aph.1Q414CrossRefPubMed

13.

Kingma JS, Burgers DMT, Monpellier VM, Wiezer MJ, Blussé van Oud-Alblas HJ, Vaughns JD, Sherwin CMT, Knibbe CAJ (2021) Oral drug dosing following bariatric surgery: general concepts and specific dosing advice. Br J ClinPharmacol 87(12):4560–4576. https://doi.org/10.1111/bcp.14913

14.

Litjens NH, van Strijen E, van Gulpen C, Mattie H, van Dissel JT, Thio HB, Nibbering PH (2004) In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 4:22. https://doi.org/10.1186/1471-2210-4-22CrossRefPubMedPubMedCentral

15.

Martins AR, Crisma AR, Masi LN, Amaral CL, Marzuca-Nassr GN, Bomfim LHM et al (2018) Attenuation of obesity and insulin resistance by fish oil supplementation is associated with improved skeletal muscle mitochondrial function in mice fed a high-fat diet. J Nutr Biochem 55:76–88. https://doi.org/10.1016/j.jnutbio.2017.11.012CrossRefPubMed

16.

Nagao H, Nishizawa H, Bamba T, Nakayama Y, Isozumi N, Nagamori S, Kanai Y, Tanaka Y, Kita S, Fukuda S, Funahashi T, Maeda N, Fukusaki E, Shimomura I (2017) Increased dynamics of tricarboxylic acid cycle and glutamate synthesis in obese adipose tissue: in vivo metabolic turnover analysis. J Biol Chem 292(11):4469–4483. https://doi.org/10.1074/jbc.M116.770172CrossRefPubMedPubMedCentral

17.

Aron-Wisnewsky J, Doré J, Clement K (2012) The importance of the gut microbiota after bariatric surgery. Nat Rev GastroenterolHepatol 9(10):590–598. https://doi.org/10.1038/nrgastro.2012.161CrossRef

18.

Zhang J, Zhang J, Wang R (2018) Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 50(3):357–368. https://doi.org/10.1080/03602532.2018.1497647CrossRefPubMed

Title: Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis
Authors: Valentina Andreozzi
Rocco Capuano
Sara Scannapieco
Francesca Barra
Beatrice d’Arco
Caterina Giordano
Miriam Caterino
Umberto De Marca
Federico Di Filippo
Maria Di Gregorio
Paolo Barone
Publication date: 27-12-2023
Publisher: Springer International Publishing
Keywords: Dimethyl Fumarate
Bariatric Surgery
Bariatric Surgery
Lymphopenia
Multiple Sclerosis
Glatiramer acetate
Published in: Neurological Sciences / Issue 6/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07283-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2024

Morgellons disease: a narrative review

Novel ERLIN2 variant expands the phenotype of Spastic Paraplegia 18

The Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19): Italian language translation and validation

A simple nomogram for predicting aspiration associated with dysphagia in hospitalized patients after stroke

Symptoms and age of prodromal Alzheimer’s disease in Down syndrome: a systematic review and meta-analysis

Correction to: Cognitive dysfunction, social behavior disorder, cerebellar ataxia, and atypical brain FDG‑PET presentation in spinocerebellar ataxia 17: a case report